FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2976840745> ?p ?o ?g. }

• W2976840745 startingPage "2761" @default.
• W2976840745 abstract "Abstract Introduction: Primary testicular lymphoma (PTL) is a rare and aggressive extranodal lymphoid malignancy with poor outcome to therapy and largely uncharacterized biology. Majority of PTLs are diffuse large B-cell lymphomas (DLBCL). Tumor associated macrophages (TAMs) are known to have prognostic impact in DLBCLs, but their role in PTLs has not been addressed. The aim of this study was to examine the association of TAMs with disease characteristics and survival in patients with PTL. Patients and methods: We identified 74 patients with PTL, all representing DLBCL histologically. Tissue microarray (TMA) was constructed from PTL samples and TMA slides were stained using multiplex immunohistochemistry (mIHC), allowing a detection of four markers (CD68, cMAF, PD-L1 and PD-L2) and nuclei simultaneously. Expression profiles were analyzed quantitatively with the image analysis software Cell Profiler. In addition, CD68, PD-L1, and PD-L2 mRNA levels were measured from 60 PTL samples. Results: For the 74 patients in the mIHC cohort, median age at diagnosis was 70 years (36-92 years) and median follow-up 67 months (range 6.7 to 120 months). Majority of the patients represented non-germinal center B-cell (non-GCB) phenotype (76%), low stage (I-II, 64%), and low/intermediate International Prognostic Index (IPI 0-2, 68%). Thirty-five patients (47%) were treated with rituximab containing chemotherapy and 36 patients (49%) received central nervous system (CNS) prophylaxis, most of them (n=34) with CNS penetrating intravenously administered chemotherapy. Altogether 34 deaths, 24 relapses and 24 lymphoma associated deaths occurred during the follow-up. 5-year overall survival (OS), disease specific survival (DSS) and progression free survival (PFS) rates were 56%, 68%, and 53%, respectively. The median proportions of PD-L1+ cells, CD68+, PDL1+CD68+, CD68+cMAF+ (M2 type), and PD-L1+CD68+cMAF+ macrophages of all cells in the tumor tissue were 15.3%, 23.7%, 9.1%, 1.3%, 0.5%, respectively. In univariate analyses with continuous variables, the proportion of PD-L1+ cells (p=0.039) and PDL1+CD68+ macrophages (p=0.043) correlated with a favorable OS. A trend towards a better OS was also observed for PD-L1+CD68+cMAF+ (p=0.090) macrophages, whereas neither PD-L1-CD68+cMAF+ macrophages nor PD-L1+CD68- cells had an impact on survival. Furthermore, no correlation with survival was found for any of the PD-L2+ cells. According to Kaplan-Meier estimates, the patients with the high proportion of PD-L1+CD68+ macrophages had a 5-year OS of 65% in comparison to 41% for those with the lower counts (p=0.026). The difference was more clear in the subgroup of patients with a stage III-IV disease (n=24, 5-year OS, 67% vs 25%, p=ns). When clinical characteristics of the patients were compared according to PD-L1+CD68+ cell counts, no significant differences in age or molecular subtype were observed between the subgroups. However, in the high PDL1+CD68+ group, more patients had stage I-II disease (p Conclusion: Our data demonstrate a significant variation in TAM contents and their phenotypes in PTL, and an association of PD-L1+ TAMs with more localized disease and favorable survival in patients with PTL. Disclosures Pollari: Novartis: Other: Conference attendance fees and travel expences; Pierre Fabre: Other: Conference attendance fees and travel expences; BMS: Other: Conference attendance fees and travel expences; Takeda: Other: Conference attendance fees and travel expences; Roche: Consultancy. Mannisto: Takeda: Honoraria, Other: Travel expence; Amgen: Other: Travel expence; Novartis: Other: Travel expence; Celgene: Other: Travel expence; Gilead: Other: Travel expence; Pfizer: Honoraria; Roche: Honoraria, Other: Travel expence; SOBI: Honoraria. Mustjoki: BMS: Honoraria, Research Funding; Novartis: Honoraria, Research Funding; Pfizer: Honoraria, Research Funding; Celgene: Honoraria; Ariad: Research Funding. Leppa: Takeda: Consultancy, Honoraria, Research Funding; Janssen Cilag: Consultancy, Research Funding; Roche: Consultancy, Honoraria, Research Funding; Merck: Consultancy, Honoraria; Bayer: Research Funding." @default.
• W2976840745 created "2019-10-03" @default.
• W2976840745 creator A5006307065 @default.
• W2976840745 creator A5007828284 @default.
• W2976840745 creator A5008868111 @default.
• W2976840745 creator A5022251064 @default.
• W2976840745 creator A5023554856 @default.
• W2976840745 creator A5024230452 @default.
• W2976840745 creator A5031007847 @default.
• W2976840745 creator A5036175948 @default.
• W2976840745 creator A5051888634 @default.
• W2976840745 creator A5055183115 @default.
• W2976840745 date "2017-12-07" @default.
• W2976840745 modified "2023-10-18" @default.
• W2976840745 title "High Amount of PD-L1+Tumor Associated Macrophages Is Associated with Better Survival in Patients with Primary Testicular Lymphoma" @default.
• W2976840745 doi "https://doi.org/10.1182/blood.v130.suppl_1.2761.2761" @default.
• W2976840745 hasPublicationYear "2017" @default.
• W2976840745 type Work @default.
• W2976840745 sameAs 2976840745 @default.
• W2976840745 citedByCount "0" @default.
• W2976840745 crossrefType "journal-article" @default.
• W2976840745 hasAuthorship W2976840745A5006307065 @default.
• W2976840745 hasAuthorship W2976840745A5007828284 @default.
• W2976840745 hasAuthorship W2976840745A5008868111 @default.
• W2976840745 hasAuthorship W2976840745A5022251064 @default.
• W2976840745 hasAuthorship W2976840745A5023554856 @default.
• W2976840745 hasAuthorship W2976840745A5024230452 @default.
• W2976840745 hasAuthorship W2976840745A5031007847 @default.
• W2976840745 hasAuthorship W2976840745A5036175948 @default.
• W2976840745 hasAuthorship W2976840745A5051888634 @default.
• W2976840745 hasAuthorship W2976840745A5055183115 @default.
• W2976840745 hasConcept C126322002 @default.
• W2976840745 hasConcept C142724271 @default.
• W2976840745 hasConcept C143998085 @default.
• W2976840745 hasConcept C159654299 @default.
• W2976840745 hasConcept C193270364 @default.
• W2976840745 hasConcept C203014093 @default.
• W2976840745 hasConcept C204232928 @default.
• W2976840745 hasConcept C2776460901 @default.
• W2976840745 hasConcept C2776694085 @default.
• W2976840745 hasConcept C2778453870 @default.
• W2976840745 hasConcept C2778476033 @default.
• W2976840745 hasConcept C2778559949 @default.
• W2976840745 hasConcept C2779338263 @default.
• W2976840745 hasConcept C2779399171 @default.
• W2976840745 hasConcept C2780653079 @default.
• W2976840745 hasConcept C71924100 @default.
• W2976840745 hasConcept C90924648 @default.
• W2976840745 hasConcept C96926380 @default.
• W2976840745 hasConceptScore W2976840745C126322002 @default.
• W2976840745 hasConceptScore W2976840745C142724271 @default.
• W2976840745 hasConceptScore W2976840745C143998085 @default.
• W2976840745 hasConceptScore W2976840745C159654299 @default.
• W2976840745 hasConceptScore W2976840745C193270364 @default.
• W2976840745 hasConceptScore W2976840745C203014093 @default.
• W2976840745 hasConceptScore W2976840745C204232928 @default.
• W2976840745 hasConceptScore W2976840745C2776460901 @default.
• W2976840745 hasConceptScore W2976840745C2776694085 @default.
• W2976840745 hasConceptScore W2976840745C2778453870 @default.
• W2976840745 hasConceptScore W2976840745C2778476033 @default.
• W2976840745 hasConceptScore W2976840745C2778559949 @default.
• W2976840745 hasConceptScore W2976840745C2779338263 @default.
• W2976840745 hasConceptScore W2976840745C2779399171 @default.
• W2976840745 hasConceptScore W2976840745C2780653079 @default.
• W2976840745 hasConceptScore W2976840745C71924100 @default.
• W2976840745 hasConceptScore W2976840745C90924648 @default.
• W2976840745 hasConceptScore W2976840745C96926380 @default.
• W2976840745 hasLocation W29768407451 @default.
• W2976840745 hasOpenAccess W2976840745 @default.
• W2976840745 hasPrimaryLocation W29768407451 @default.
• W2976840745 hasRelatedWork W2547016742 @default.
• W2976840745 hasRelatedWork W2553798532 @default.
• W2976840745 hasRelatedWork W2555338873 @default.
• W2976840745 hasRelatedWork W2565691099 @default.
• W2976840745 hasRelatedWork W2596208424 @default.
• W2976840745 hasRelatedWork W2609763215 @default.
• W2976840745 hasRelatedWork W2612248406 @default.
• W2976840745 hasRelatedWork W2622169868 @default.
• W2976840745 hasRelatedWork W2785425975 @default.
• W2976840745 hasRelatedWork W2786742505 @default.
• W2976840745 hasRelatedWork W2901964955 @default.
• W2976840745 hasRelatedWork W2909672303 @default.
• W2976840745 hasRelatedWork W2915858405 @default.
• W2976840745 hasRelatedWork W2940859780 @default.
• W2976840745 hasRelatedWork W2967137243 @default.
• W2976840745 hasRelatedWork W2979369099 @default.
• W2976840745 hasRelatedWork W2980271737 @default.
• W2976840745 hasRelatedWork W2989038715 @default.
• W2976840745 hasRelatedWork W2989541021 @default.
• W2976840745 hasRelatedWork W3171344400 @default.
• W2976840745 hasVolume "130" @default.
• W2976840745 isParatext "false" @default.
• W2976840745 isRetracted "false" @default.
• W2976840745 magId "2976840745" @default.
• W2976840745 workType "article" @default.